Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.

Authors:
Hideki Murata
Hideki Murata
Shizuoka Cancer Center Hospital
Japan
Koji Yoshimoto
Koji Yoshimoto
Kyushu University
Japan
Ryusuke Hatae
Ryusuke Hatae
National Hospital Organization
Japan
Yojiro Akagi
Yojiro Akagi
Graduate School of Medical Sciences
Japan
Masahiro Mizoguchi
Masahiro Mizoguchi
Graduate School of Medical Sciences
Nobuhiro Hata
Nobuhiro Hata
Kyushu University
Japan
Daisuke Kuga
Daisuke Kuga
Graduate School of Medical Sciences
Akira Nakamizo
Akira Nakamizo
Graduate School of Medical Sciences

J Neurooncol 2015 Oct 14;125(1):33-41. Epub 2015 Aug 14.

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11060-015-1886
Web Search
http://link.springer.com/10.1007/s11060-015-1886-y
Publisher Site
http://dx.doi.org/10.1007/s11060-015-1886-yDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
October 2015
15 Reads

Publication Analysis

Top Keywords

proneural mesenchymal
20
mes score
12
hdac7 expression
12
gene expression
12
expression
10
samples grade
8
p-m score
8
malignant transformation
8
mesenchymal glioblastoma
8
tumor recurrence
8
chromatin-modifying gene
8
mesenchymal subtypes
8
temporospatial dynamics
8
score
7
glioblastoma
6
mesenchymal
5
markers
5
tumor
5
proneural
5
transformation tumor
4

Similar Publications